286 related articles for article (PubMed ID: 35975761)
1. New investigational agents for the treatment of major depressive disorder.
Pochwat B; Krupa AJ; Siwek M; Szewczyk B
Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761
[TBL] [Abstract][Full Text] [Related]
2. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
3. Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.
Chaki S; Fukumoto K
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871246
[TBL] [Abstract][Full Text] [Related]
4. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A
Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583
[TBL] [Abstract][Full Text] [Related]
5. The possible place for psychedelics in pharmacotherapy of mental disorders.
Wojtas A
Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
[TBL] [Abstract][Full Text] [Related]
6. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
[TBL] [Abstract][Full Text] [Related]
7. Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions.
Onisiforou A; Georgiou P; Zanos P
Pharmacol Biochem Behav; 2023 Feb; 223():173531. PubMed ID: 36841543
[TBL] [Abstract][Full Text] [Related]
8. NMDA antagonists under investigation for the treatment of major depressive disorder.
Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
[TBL] [Abstract][Full Text] [Related]
9. mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.
Chaki S; Watanabe M
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1451-1462. PubMed ID: 36715750
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L
Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacological innovation in the treatment of depression.
Witkin JM; Golani LK; Smith JL
Expert Rev Clin Pharmacol; 2023 Apr; 16(4):349-362. PubMed ID: 37000975
[TBL] [Abstract][Full Text] [Related]
12. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
13. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C
Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993
[TBL] [Abstract][Full Text] [Related]
14. An update on NMDA antagonists in depression.
Pochwat B; Nowak G; Szewczyk B
Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
[No Abstract] [Full Text] [Related]
15. The role of serotonin neurotransmission in rapid antidepressant actions.
Pehrson AL; Roberts D; Khawaja A; McNair R
Psychopharmacology (Berl); 2022 Jun; 239(6):1823-1838. PubMed ID: 35333951
[TBL] [Abstract][Full Text] [Related]
16. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
Dogra S; Conn PJ
Neuropharmacology; 2021 Sep; 196():108687. PubMed ID: 34175327
[TBL] [Abstract][Full Text] [Related]
17. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM
Expert Opin Drug Discov; 2022 Oct; 17(10):1131-1146. PubMed ID: 35934973
[TBL] [Abstract][Full Text] [Related]
18. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.
Pałucha-Poniewiera A; Podkowa K; Rafało-Ulińska A
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110239. PubMed ID: 33400944
[TBL] [Abstract][Full Text] [Related]
19. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
Musazzi L
Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
[TBL] [Abstract][Full Text] [Related]
20. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.
Johnston JN; Kadriu B; Allen J; Gilbert JR; Henter ID; Zarate CA
Neuropharmacology; 2023 Mar; 226():109422. PubMed ID: 36646310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
